Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Overview of Paragon 28 Inc
Paragon 28 Inc (FNA) is a specialized medical device company dedicated exclusively to the foot and ankle orthopedic segment. Established in 2010 with a clear mission to blend surgical innovation and quality, the company has built a comprehensive portfolio of surgical solutions targeting complex foot and ankle procedures. Utilizing advanced technologies in orthopedic implants and surgical instrumentation, Paragon 28 aims to set a benchmark in innovation and operational efficiency within the medical device industry.
Mission and Core Values
From its humble beginnings as a small, family-based business, Paragon 28 has consistently maintained its core ideals of innovation, quality, and dedicated service. The company's name is a tribute to its exclusive focus on foot and ankle surgery, with the number '28' symbolizing the anatomical complexity of the human foot. Central to its mission is the drive to advance the science of foot and ankle surgery by integrating diverse surgical philosophies from global thought leaders, ensuring that each surgical solution meets stringent biomechanical and clinical standards.
Comprehensive Product Portfolio
Paragon 28 offers an extensive suite of nearly 80 proprietary surgical product systems. These include a range of orthopedic devices such as plates, plating systems, screws, staples, and nails. These products are meticulously designed to address a variety of foot and ankle procedures including:
- Ankle reconstruction and fixation for complex fractures and musculoskeletal trauma
- Fracture fixation solutions that ensure stability and promote healing
- Procedural instrumentation for deformity corrections, hallux valgus, hammertoe, and flatfoot conditions
- Innovative solutions for specialized conditions such as Charcot foot and progressive collapsing foot deformity
Operational Excellence and Distribution
The company leverages a dedicated and highly trained sales and distribution network to ensure that its advanced orthopedic devices reach a wide network of surgical centers and hospitals, primarily within the United States. This customer-centric approach, combined with efficient operational practices, allows Paragon 28 to address the dual challenges of increasing pricing pressures and reimbursement complexities within the healthcare sector.
Competitive Position and Industry Impact
Operating within the dynamic and competitive landscape of orthopedics, Paragon 28 has distinguished itself through its unwavering focus on the foot and ankle segment. By prioritizing innovation and tailoring its product offerings to meet the precise needs of both patients and surgeons, the company has established a strong operational niche. Its strategy of blending global surgical insights with a rigorous quality framework enables it to create products that are not only clinically relevant but also easily reproducible in diverse surgical settings. This distinctive positioning highlights the company’s commitment to improving patient outcomes while maintaining operational efficiency.
Strategy and Business Model
Paragon 28's business model is anchored in its commitment to three primary pillars:
- Creation and Innovation: Investing in research and development to refine surgical techniques and develop devices that address specific clinical challenges in the foot and ankle spectrum.
- Focused Service: Establishing a robust distribution network that ensures timely delivery and superior customer service, which is critical for high-stakes surgical environments.
- Efficient Practices: Implementing operational efficiencies to navigate challenges related to evolving reimbursement frameworks and pricing pressures, thereby sustaining a cycle of quality and innovation.
Expertise and Authoritativeness
The company's process of integrating varied surgical philosophies into its product design reflects deep industry expertise. Paragon 28’s commitment to ongoing research and development, along with its emphasis on user-friendly yet technologically advanced products, positions it as a trusted name among orthopedic surgeons. The company’s continuous efforts in refining its product systems set a high standard of care in the specialized field of foot and ankle surgery.
Understanding the Technology and Innovation
In the realm of medical devices, technological innovation is crucial. Paragon 28 harnesses cutting-edge manufacturing techniques and research-driven insights to build devices that enhance surgical precision and reliability. This detailed approach ensures that each product not only conforms to current clinical requirements but also anticipates the nuanced challenges surgeons face during delicate procedures. The application of advanced orthopedic implant technologies and state-of-the-art design principles underscores the company’s commitment to facilitating optimal patient outcomes.
Market Significance and Industry Relevance
Although Paragon 28 operates within a specialized niche of the orthopedic implant market, the company’s influence is profound due to its unwavering focus on quality, innovation, and customer service. Its strategic approach, combined with a suite of versatile surgical solutions, effectively addresses critical gaps in the foot and ankle surgical procedural space. This specialization allows the company to serve a targeted customer base that includes orthopedic surgeons, hospitals, and outpatient surgical centers, all of which rely on dependable and innovative surgical solutions to improve patient care.
Conclusion
In summary, Paragon 28 Inc stands as a comprehensive, innovation-driven entity in the orthopedic medical device arena. Its focused mission, extensive product portfolio, and commitment to blending global surgical insights with efficient, reliable service have positioned it as a pivotal player in addressing the challenges of foot and ankle surgery. Through its attention to detail in both product development and operational execution, Paragon 28 offers a detailed case study of how concentrated expertise can drive significant advancements in medical technology.
Paragon 28, a medical device company in the foot and ankle orthopedic market, reported its Q3 2024 financial results and raised its 2024 net revenue guidance. The company recorded global net revenue of $62.3 million, marking 18.1% reported growth compared to the prior year. U.S. net revenue was $51.2 million, a 14.8% increase, while international net revenue was $11.2 million, up 35.7%. Despite a net loss of $12.3 million, this was an improvement from the $11.2 million loss in Q3 2023. Gross margin decreased to 74.1% from 77.4%. Operating expenses rose 6.3% to $54.6 million. Adjusted EBITDA turned positive to $0.4 million. Free Cash Flow improved by 69.5% year-over-year. The company raised its 2024 net revenue guidance to $252-$256 million, representing 16.5%-18.3% growth.
Rigrodsky Law has initiated an investigation into Paragon 28 (NYSE:FNA) regarding potential claims against its officers and directors. The investigation focuses on whether the company and its leadership issued materially misleading information or failed to disclose material information to investors concerning financial outlook and internal controls over financial reporting. The investigation covers shareholders who acquired Paragon shares on or before May 5, 2023. Affected shareholders can learn more about their rights at no cost through Rigrodsky Law's website or by contacting their representative.
Paragon 28 (NYSE: FNA), a leading medical device company focused on the foot and ankle orthopedic market, has announced it will report its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a conference call and webcast at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time on the same day to discuss the results.
Investors can participate in the conference call by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. The webcast will be available on the 'Investors' section of Paragon 28's website at ir.paragon28.com and will be archived for replay for at least 90 days after the event.
Paragon 28 (NYSE: FNA) has launched the Phantom® Fibula Nail System, offering surgeons a less invasive option for treating ankle fractures. This system has shown fewer soft tissue complications, implant removals, and fracture nonunion compared to traditional plate and screw fixation. The system includes innovative features such as:
- Instrumentation for anatomic reduction and proper implant placement
- An Entry K-Wire Guide for correct starting point identification
- A Curved Reamer Guide for proper implant angle
- Screws that thread into the nail
- An expandable proximal locking mechanism
- Compatibility with Paragon 28's syndesmotic implant options
The Phantom® Fibula Nail System is delivered in one surgical tray with sterile packed implants, simplifying surgical workflow and inventory management. It joins Paragon 28's extensive foot and ankle fracture portfolio.
Paragon 28 (NYSE: FNA) has introduced a novel Right-Angle Drill for its APEX 3D™ Total Ankle Replacement System. This new tool is designed to improve tibia preparation before implanting the APEX 3D™ tibia implant. The drill uses a linear guide to precisely create vertical holes in the tibia, ensuring ideal peg placement and a stable implant interface.
This addition is part of a series of instrumentation enhancements to the APEX 3D™ system, including recently released Polishing Blocks, Square Tip Drill, and next-generation Off-Set Impaction Handle. These improvements aim to enhance tibia preparation, contributing to the long-term success of ankle replacements and improving surgeon experience and patient outcomes.
Paragon 28 (NYSE: FNA) has launched the R3FLEX™ Stabilization System, designed to restore stability to ankle syndesmosis after injuries from ankle fractures or high ankle sprains. The system allows surgeons to precisely adjust and visualize tension during repair with a simple handle turn. Key features include:
- Restores soft tissue to a more natural anatomy
- Mitigates arthritic response
- Minimizes risk of hardware removal
- Tibial implant rests on internal surface, reducing risk to saphenous nerve and vein
- Strong repair construct less susceptible to elongation
- Allows controlled micromotion similar to uninjured state
- Delivered in a single sterile kit for simplified workflow
The R3FLEX™ system enhances Paragon 28's soft tissue portfolio, providing a comprehensive solution for foot and ankle soft tissue needs.
Paragon 28 (NYSE: FNA) has launched the SMART28℠ Case Management Portal, a platform leveraging AI for coordinating patient-specific surgical plans. This marks the first major release in Paragon 28's SMART28℠ ecosystem, aimed at improving foot and ankle treatments through advanced technologies.
The portal's first module, SMART Bun-Yo-Matic℠, focuses on bunion correction. It offers unique features like 3D anatomy visualization from X-rays and AI-driven algorithms for tailored surgical plans. Dr. Cesar De Cesar Netto, an early user, praised the system's precision in Hallux Valgus surgery.
CEO Albert DaCosta emphasized the portal's significance for the future of foot and ankle surgery, highlighting its efficiency in 3D procedure planning and precise implementation. The SMART28℠ Case Management Portal is set to expand with additional modules for various foot and ankle conditions.
Paragon 28 (NYSE: FNA) has appointed Chadi Chahine as CFO and EVP of Supply Chain Operations, effective August 5, 2024. The company reported Q2 2024 financial results, with global revenue of $61.0 million, representing 19.6% growth. Key highlights include:
- Narrowed 2024 net revenue guidance to $249-$255 million
- Initiated operational efficiency strategy, including 7% workforce reduction
- Q2 gross margin at 75.0%, down from 77.3% in Q2 2023
- Net loss of $13.8 million in Q2 2024
- Adjusted EBITDA loss of $3.0 million, an improvement from $5.4 million loss in Q2 2023
The company also announced a restatement of financial statements for FY 2023 and Q1 2024 due to material accounting errors in inventory calculations.
Paragon 28 (NYSE: FNA), a leading medical device company focused on the foot and ankle orthopedic market, has announced it will report its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time to discuss the results. Investors can join the call by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 389675.
Additionally, Paragon 28's management team will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference on August 14, at 8:00 a.m. Eastern Time. Both events will be webcast live and archived on the company's investor relations website at ir.paragon28.com.
Paragon 28, a leading medical device company, reported a record net revenue of $61.1 million for the first quarter of 2024, up 17.4% from the same period in 2023. The company also reaffirmed its 2024 net revenue guidance of $249 million to $259 million, expecting 15.1% to 19.7% growth compared to 2023. Despite a decrease in gross profit margin and an increase in operating expenses, the company remains optimistic about sustainable growth driven by new product launches and expanded commercial channels.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
What does Paragon 28 Inc specialize in?
What types of products does Paragon 28 offer?
How does Paragon 28 generate revenue?
What are the core values of Paragon 28 Inc?
How does Paragon 28 maintain industry expertise?
What distinguishes Paragon 28 in the competitive orthopedic market?
Who are the primary customers of Paragon 28?
How does Paragon 28 address the challenges in the healthcare market?
